Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond.When phosphodiesterase is mentioned, it usually refers to cyclic nucleotide phosphodiesterases, which are discussed below and have significant clinical implications. There are numerous other families of phosphodiesterases, however, including the phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, in addition to a large number of less well-studied small-molecule phosphodiesterases.A group of enzymes known as cyclic nucleotide phosphodiesterases breaks down the phosphodiester bond in the second messenger molecules cAMP and cGMP. Within subcellular domains, they control the cyclic nucleotide signaling's amplitude, duration, and localization. Therefore, PDEs play a crucial role in controlling the signal transduction process that these second messenger molecules mediate.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V79157 | Dipyridamole-d16 (Dipyridamole-d16) | Dipyridamole-d16 is the deuterated form of Dipyridamole. | ||
V72033 | Dipyridamole-d20 (Dipyridamole d20) | 1189983-52-5 | Dipyridamole-d20 is the deuterated form of Dipyridamole. | |
V72083 | Doxofylline-d4 (doxofylline d4) | 1346599-13-0 | Doxofylline-d4 is the deuterium labelled form of Doxofylline. | |
V72032 | Doxofylline-d6 (doxofylline d6) | 1219805-99-8 | Doxofylline-d6 is the deuterium labelled form of Doxofylline. | |
V2193 | DSR-141562 | 2007975-22-4 | DSR-141562 is a novel, potent, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. | |
V4471 | Edelinontrine (PF-04447943) | 1082744-20-4 | PF-04447943 (PF04447943) is a novel and potent inhibitor of human recombinantPDE9A with the potential for the treatment of cognitive disorders. | |
V83236 | EHNA HCl | 51350-19-7 | EHNA HCl is a PDE2 inhibitor | |
V30046 | EHNA hydrochloride | 58337-38-5 | EHNA HCl, the hydrochloride salt of EHNA, is a novel and potent inhibitor of adenosine deaminase, also an inhibitor of cGMP-stimulated phosphodiesterase (PDE2) with IC50 of 0.8 - 4 μM. | |
V72019 | Enpp-1-IN-12 | 2631703-41-6 | Enpp-1-IN-12 (Compound 43) is a potent and orally bioactive ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor (antagonist) with Ki of 41 nM. | |
V72070 | Enpp-1-IN-15 | 2756218-99-0 | Enpp-1-IN-15 (Compound 88a) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp-1) inhibitor (antagonist) with Ki of 0.00586 nM. | |
V72023 | Enpp-1-IN-16 | 2289739-47-3 | Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. | |
V72096 | Enpp-1-IN-17 | 2289736-54-3 | Enpp-1-IN-17 (example 274) is a potent ENPP1 inhibitor (antagonist) with inhibition constants (Kis) of cGAMP and ATP hydrolysis of 100 nM-1 μM and > 1 μM, respectively. | |
V72074 | Enpp-1-IN-19 | 2738583-25-8 | Enpp-1-IN-19 (compound 29f) is an orally bioavailable ENPP1 inhibitor that can suppress cGAMP hydrolysis by ENPP1 (IC50=68 nM). | |
V72084 | Enpp-1-IN-4 | 2376600-89-2 | Enpp-1-IN-4 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). | |
V72069 | Enpp-1-IN-5 | 2230916-95-5 | Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). | |
V72095 | Enpp-1-IN-6 | 2718971-29-8 | Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). | |
V79310 | Enpp-1-IN-7 | Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). | ||
V72091 | Enpp-1-IN-8 | 2718971-08-3 | Enpp-1-IN-8 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). | |
V72076 | Enpp-1-IN-9 | 2718970-70-6 | Enpp-1-IN-9 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). | |
V40090 | ent-Tadalafil | 629652-72-8 | ent-Tadalafil(ent-IC-351) is a cis-enantiomer and animpurity of Tadalafil, which is an inhibitor of PDE5/phosphodiesterase 5 approved as an oral drug for treating erectile dysfunction (ED). |